Translation 2025
DPUK's next translational dementia research conference - Translation 2025 is on 13-14th March.
TRANSLATION 2025 is a two-day conference on 13-14th March bringing together leading researchers to discuss the latest discoveries and innovations in dementia research.
We will be revealing more information about our themes, speakers and features of the event over the next few months.
REGISTER YOUR INTEREST IN ATTENDING
We'll make sure you know when our Early Bird booking opens and keep you up to date with news about the conference.
SCOPE OF THE CONFERENCE
Recent new drugs impacting dementia's progression, new drives in data research, biomarker studies, international collaborations, a growing infrastructure, effective trials delivery capacity are all important elements for translational research. So too is experimental research as we seek to find new disease-modifying treatments for dementia.
We are expecting 250 delegates, from academia, industry and the third sector at The Congress Centre in London who are hosting us for the second time.
In addition to the main session during our busy 2-day conference, we are holding an Early Career Researcher morning which has proved extremely popular for those in the earlier stages of research in this field.
The conference will be at The Congress Centre, Great Russell Street, London on 13-14th March 2025.
You can watch speakers from previous conference on our video channel.
Our Keynote speakers at Translation 2025 are amongst the world's leading authorities in their fields of research.
|
Professor Sir John Hardy is the Chair of Molecular Biology of Neurological Disease at the UCL Institute of Neurology and a Group Lead at the UK Dementia Research Institute. He contributed to a critical breakthrough in understanding what happens in the brain with the onset of Alzheimer’s disease. Since then, he has led broader effort to understand the genetic factors behind other degenerative brain diseases, including Parkinson’s disease and motor neuron disease. John discovered that a mutation in the gene for amyloid precursor protein (APP) caused deposits of a substance called amyloid to form in brain tissue, associated with early-onset Alzheimer’s. Deposits of amyloid, which kills brain cells, later proved to be a primary cause of the disease. Professor Hardy’s is now harnessing the power of whole-genome sequencing to reveal the more complex interactions between genes and the environment that increase the risk of neurodegenerative disease. He is a Fellow of the Royal Society and was knighted in the 2022 New Year’s honours. |
|
Professor Arthur Toga is Provost Professor of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Radiology and Biomedical Engineering, and Director of the USC Mark and Mary Stevens Institute of Neuroimaging and Informatics. One of the world’s leading authorities on neuroimaging, informatics, AI applications in neuroscience, mapping brain structure and function, and brain atlasing. Dr. Toga’s research focus is in neurodegenerative disease and specifically works on Alzheimer’s disease. His interdisciplinary work led to the creation of the Laboratory of Neuro Imaging (LONI), which he also directs and is one of the most advanced multidisciplinary neurological research centers in the world serving numerous multisite neuroscience projects globally. Funded by National Institutes of Health (NIH) grants as well as industry partners, LONI houses one of the largest computing facilities and largest brain image repository in the world. He is an author or co-author of more than 950 peer-reviewed papers, 1200 abstracts and 80 book chapters or books, among them, the Brain Mapping Trilogy. He is the founding editor of the journal NeuroImage. Dr. Toga has received numerous awards for his ran Award for Scientific Innovation and Giovanni DiChiro Award for Outstanding Scientific Research and teaching, including the Pioneer in Medicine Award, Smithsoni. He holds the Ghada Irani chair in Neuroscience and has been on the Thomson Reuters' Highly Cited Researchers for many years. |
|
Professor Catherine Mummery is a Professor of Neurology and consultant neurologist at the National Hospital for Neurology and Neurosurgery. She is chair of the NIHR Dementia Translational Research Collaboration, and Director of the NIHR UK Dementia Trials Network, building a national unified trials network for early phase clinical trials and working with the Mission to accelerate and enhance dementia translational research in novel treatments. She is Head of Clinical Trials at the Dementia Research Centre at University College London. She has been chief investigator on over 20 early phase drug trials of potential disease modifying agents in sporadic Alzheimer’s disease (AD), and genetic forms of AD and frontotemporal dementia. As clinical lead for the UCL Neurogenetic Therapies Programme, she leads a programme of innovative collaboration between industry and academia to accelerate progress in genetic therapies in dementia. Her driving ambition is to ensure we not only have treatments that can alter the course of neurodegenerative diseases like Alzheimer’s, but that we can deliver them promptly, safely and equitably. |
|
Professor Henrik Zetterberg is Professor of Neurochemistry, Senior Consultant in Clinical Chemistry at the University of Gothenberg in Sweden. He is a Group Lead at the UK Dementia Research Institute and leads the UK Biomarker Factory. His research includes the development of methods for early diagnostics for frontotemporal dementia through the use of Biomarkers.] In 2020, a team of scientists led by Zetterberg published results regarding a new diagnostic for Alzheimer's disease based on protein concentrations in cerebrospinal fluid, which is a colorless fluid surrounding the brain and spinal cord. The test was reported to have an accuracy of around 90% and could detect the disease about two decades before significant symptoms were present. |
Early Career Researchers are important to Translation 2025. Cost should not be an issue and we are rolling out a heavily discounted rate very shortly. We will also be holding a session designed for ECRs at the start of the conference. Watch out for opportunities to present posters and give Flash Talks too.
DISCOUNTED RATEEnjoy the whole conference for only £60. We appreciate that few ECRs can stretch to the full cost of the conference. So, there is a special ECR rate of £60 which includes attendance for the whole of the conference, including our ECR morning. |
|
ECR WORKSHOP - 13TH MarchDedicated to Early Career Researchers, this special morning workshop will be held immediately before the main conference begins. It has proved to be a highlight for many EVRs and focuses on very useful talks about the resources available to help researchers from DPUK, Alzheimer's Research UK and many others.
|
|
CRITERIA TO QUALIFY AS AN ECR AT TRANSLATION CONFERENCES
Applicant skills and experience |
|
ECR: Definition |
DPUK’s formal definition of an ECR is an individual who is within ten years of the award of their PhD or equivalent professional training, or an individual who is within six years of their first academic appointment. These durations exclude any period of career break, e.g. for family care or health reasons. The ‘first academic appointment’ is defined as the first paid contract of employment, either full-time or part-time, which lists research and/or teaching as the primary functions. |